Garching / Munich, Germany, August 19, 2025 – ITM, a leading biotechnology company specializing in radiopharmaceuticals, has announced the presentation of new data, including efficacy, safety, and subgroup analysis, from its COMPETE trial. The findings will be shared in an oral presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany, from October 17-21, 2025. Additionally, ITM will host an educational event designed to foster scientific discussions among emerging healthcare professionals from various disciplines within the field of theranostics.
Oral Presentation Details
Dr. Jaume Capdevila, the study investigator, will present the data in an oral presentation titled “Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial,” on Saturday, October 18, during the NETs and Endocrine Tumors Proffered Paper Session, from 10:15 am to 11:45 am CEST.
Abstract Number: 1706O
Date and Time: Saturday, October 18, 2025 from 10:15 am – 11:45 am CEST
Location: Karlsruhe Auditorium – Hall 5.2
Educational Event Details
ITM’s educational event, titled “Precision Meets Practice: A NETworking Experience,” will be moderated by NET expert Dr. Angela Lamarca and held on Sunday, October 19, 2025, from 6:30 pm – 10:00 pm CEST. This medical networking event aims to unite emerging healthcare professionals specializing in oncology, nuclear medicine, endocrinology, and gastroenterology. The goal is to promote cross-disciplinary collaboration and discussions regarding NETs and theranostics. Due to limited availability, interested physicians are encouraged to register by contacting the following email address: .
Date and Time: Sunday, October 19, 2025 from 6:30 pm – 10:00 pm CEST
Location: Berlin, Germany; further details will be provided upon registration
ITM will also have a booth at the conference (booth number: 2030), showcasing information about the company’s radiopharmaceutical therapy (RPT) innovations.
About the COMPETE Trial
The COMPETE trial (NCT03049189) assessed 177Lu-edotreotide (ITM-11), an investigational, targeted radiotherapeutic agent developed by ITM, in comparison to everolimus, a targeted molecular therapy. The study involved patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The trial achieved its primary endpoint, with 177Lu-edotreotide demonstrating a clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is also under evaluation in COMPOSE, a Phase 3 study involving patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors.
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, focuses on creating innovative radiopharmaceutical treatments and diagnostics for difficult-to-treat tumors. Our goal is to meet the needs of cancer patients, clinicians, and partners by excelling in the development, production, and global supply of medical radioisotopes. With the principle of improved patient outcomes guiding our work, ITM is advancing a diverse precision oncology pipeline. This includes multiple Phase 3 studies that combine the company’s high-quality radioisotopes with various targeting molecules. By utilizing our two decades of expertise in radiopharma, our central position in the industry, and our established global network, ITM aims to provide patients with more effective, targeted treatments to improve clinical outcomes and quality of life.
ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:
Attachment
“`
